Authors:
M. A. Hernandes, J. Elias Jr, A. C. Teixeira, V. F. Muglia, M. Koenigkam-Santos, F. F. Souza, A. L. C. Martinelli, A. K. Sankarankutty, O. Castro e Silva; Ribeirão Prêto/BR
DOI:
10.1594/ecr2010/C-0030
Results
All patients presented with chronic liver disease, which etiologic distribution is shown in figures 1 and 2.
Fifty percent only of the patients were included in the screening program for HCC detection, based on ultrasound and AFP dosages in intervals of 4 to 6 months.
Ultrasound has missed infiltrative HCC detection in 10/20 patients (50%) while CT has missed in 2/20 patients (10%). All 18 patients studied by MRI were diagnosed for infiltrative HCC.
Four patients were classified as small infiltrative diffuse-type HCC, which represented 15.3% of diffuse-type HCC, and 2.2 % of all patients with HCC.
Mean serum AFP level was 1451.9 ng/ml, varying from 12.46 to 3630 ng/ml. Only six patients (23%) presented with AFP lower than 200 ng/ml in the period close to the diagnostic confirmation (12.46; 16.46; 31.34; 32.19; 52.39 and 143.99 ng/ml). There was no difference of AFP levels between small infiltrative and diffuse disseminated HCC groups (P = 0.71).
Mortality rate for diffuse disseminated HCC group was 72.7%, while for small infiltrative diffuse HCC was 0%. The time interval average from the diagnose to death was 60 days +/- 71, varying from 6 to 220 days.